Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JTAOC
ADC Name
nBT062-SMCC-DM1
Synonyms
nBT062 SMCC DM1
   Click to Show/Hide
Organization
ImmunoGen, Inc.; Biotest AG
Drug Status
Investigative
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
Drug-to-Antibody Ratio
3.5
Structure
Antibody Name
Indatuximab
  Antibody Info 
Antigen Name
Syndecan-1 (SDC1)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Emtansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 78.02
%
MOLP-8 cells
Plasma cell myeloma
Tumor Growth Inhibition value (TGI) 
≈ 93.32
%
MOLP-8 cells
Plasma cell myeloma
Tumor Growth Inhibition value (TGI) 
≈ 94.27
%
MOLP-8 cells
Plasma cell myeloma
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.1
nM
MOLP-8 cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
> 100
nM
BJAB cells
Burkitt lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 78.02% (Day 30) Positive CD138 expression (CD138 +++/++)
Method Description
MOLP-8 cells (1.5x107 cells per mouse) suspended in a 50:50 mixture of serum free media and matrigel were injected subcutaneously in the area under the right shoulder in 100 ul. Nine groups (n=6) were treated with a single intravenous injection of ADCs, each at doses of 250 ug/kg.
In Vivo Model MOLP-8 CDX model
In Vitro Model Plasma cell myeloma MOLP-8 cells CVCL_2124
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 93.32% (Day 30) Positive CD138 expression (CD138 +++/++)
Method Description
MOLP-8 cells (1.5x107 cells per mouse) suspended in a 50:50 mixture of serum free media and matrigel were injected subcutaneously in the area under the right shoulder in 100 ul. Nine groups (n=6) were treated with a single intravenous injection of ADCs, each at doses of 250 ug/kg per week (five weeks).
In Vivo Model MOLP-8 CDX model
In Vitro Model Plasma cell myeloma MOLP-8 cells CVCL_2124
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.27% (Day 30) Positive CD138 expression (CD138 +++/++)
Method Description
MOLP-8 cells (1.5x107 cells per mouse) suspended in a 50:50 mixture of serum free media and matrigel were injected subcutaneously in the area under the right shoulder in 100 ul. Nine groups (n=6) were treated with a single intravenous injection of ADCs, each at doses of 450 ug/kg.
In Vivo Model MOLP-8 CDX model
In Vitro Model Plasma cell myeloma MOLP-8 cells CVCL_2124
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.10 nM-1.00 nM Positive CD138 expression (CD138 +++/++)
Method Description
CD138+ MOLP-8 cells were seeded in flat bottom plates at 3000 cells/well. CD138- BJAB control cells were seeded at 1000 cells/weli. The cells were treated with nBT062-SPDB-DM4nBT062-SPP-DM1 or nBT062-SMCC-DM1 at different concentrations for five days.
In Vitro Model Plasma cell myeloma MOLP-8 cells CVCL_2124
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 100 nM Negative CD138 expression (CD138 -)
Method Description
CD138+ MOLP-8 cells were seeded in flat bottom plates at 3000 cells/well. CD138- BJAB control cells were seeded at 1000 cells/weli. The cells were treated with nBT062-SPDB-DM4nBT062-SPP-DM1 or nBT062-SMCC-DM1 at different concentrations for five days.
In Vitro Model Burkitt lymphoma BJAB cells CVCL_5711
References
Ref 1 Immunoconjugates targeting cd138 and uses thereof; 2009-07-02.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.